You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

 

Online download statistics by month:

Online download statistics by month: June 2021 to February 2026

AbstractFullPdf
Jun 2021873882235
Jul 202129029066
Aug 202119219255
Sep 202119018954
Oct 202117517556
Nov 202121821766
Dec 202115215744
Jan 202214515247
Feb 202212412739
Mar 202211412044
Apr 202214115851
May 202210711331
Jun 202213414644
Jul 202212213839
Aug 202214114535
Sep 202212512828
Oct 202215516442
Nov 202215716034
Dec 202212512531
Jan 202313514033
Feb 202316316525
Mar 202313214046
Apr 202310911023
May 202313413737
Jun 202311411734
Jul 2023888818
Aug 202311011014
Sep 202385859
Oct 202311312327
Nov 202311111319
Dec 2023999919
Jan 2024576020
Feb 2024838332
Mar 202410110277
Apr 202410210344
May 202411211339
Jun 20249810029
Jul 202413713832
Aug 202411211314
Sep 2024636432
Oct 2024929335
Nov 202412212619
Dec 202418819530
Jan 202516716735
Feb 202521421533
Mar 202511211241
Apr 202514914960
May 2025949437
Jun 2025747523
Jul 2025110
Feb 2026110
Total715273091977